TB-500 + AOD-9604 Stack: When to Pick One Over the Other (or Both)

What TB-500 and AOD-9604 Actually Do (and Why They Are Often Confused)

These two peptides show up together on forums and in clinic conversations, but they act through entirely different pathways. Knowing that distinction is the starting point for any rational stacking decision.

TB-500: Thymosin Beta-4 Fragment and Tissue Repair

TB-500 is a synthetic analogue of the active region of thymosin beta-4, a naturally occurring 43-amino-acid peptide found at high concentrations in platelets, wound fluid, and cardiac tissue. Its core mechanism is actin sequestration. By binding G-actin, TB-500 increases the pool of monomeric actin available for cytoskeletal remodeling, which accelerates cell migration into wound sites [1].

Animal studies have shown it reduces cardiac fibrosis after myocardial infarction. A 2004 paper in Nature Medicine (Bock-Marquette et al.) demonstrated that thymosin beta-4 activated cardiac progenitor cells and improved cardiac function in rodent infarct models [2]. Separately, a 2010 study published in the Journal of Cell Science confirmed TB-500's role in promoting corneal and dermal wound closure through the Akt/ILK signaling pathway [3].

TB-500 also suppresses inflammatory cytokines. In a rat tendon-injury model, subcutaneous thymosin beta-4 reduced TNF-alpha and IL-6 at the injury site within 72 hours of administration [4]. This dual action (pro-repair and anti-inflammatory) is what makes it attractive for musculoskeletal recovery.

AOD-9604: The Fat-Loss Fragment

AOD-9604 is residues 176 to 191 of human growth hormone, isolated because this C-terminal region contains the receptor-binding domain responsible for lipolysis. Unlike full-spectrum hGH or peptides that stimulate GH release (such as CJC-1295 or ipamorelin), AOD-9604 does not raise IGF-1 levels meaningfully and does not carry the proliferative risks associated with excess GH signaling [5].

Its lipolytic action runs through beta-3 adrenergic receptor stimulation and inhibition of fatty acid synthesis. In the METABOL study (a Phase IIb randomized, placebo-controlled trial, N=300), daily oral AOD-9604 at 1 mg produced modest but statistically significant reductions in body weight over 24 weeks compared to placebo, though the absolute effect size did not support approval [6]. The subcutaneous route used in research settings may produce larger bioavailable concentrations than the oral doses tested in that trial.

The Mechanistic Case for Stacking Them

TB-500 and AOD-9604 do not share a pathway. They do not compete for the same receptors. They are unlikely to produce pharmacokinetic interactions given their different molecular sizes and clearance routes.

Why the Combination Is Biologically Additive

Because TB-500 works on cytoskeletal dynamics and AOD-9604 works on lipid metabolism, combining them is additive rather than redundant. An athlete recovering from a hamstring tear who also wants to manage body composition during a forced rest period has two distinct needs that one peptide alone cannot meet. TB-500 addresses the tissue repair side. AOD-9604 addresses the energy partitioning side during caloric surplus or restricted activity.

No published randomized controlled trial has tested this specific combination in humans. That gap must be stated plainly. Evidence for the stack is extrapolated from the individual mechanistic and clinical data for each peptide, plus practitioner-reported outcomes.

When the Stack Is Overkill

If the only goal is fat loss and the person is healthy with no active injury, TB-500 adds cost without proportional benefit. AOD-9604 alone at 250 to 500 mcg subcutaneous once daily is the appropriate starting point.

Conversely, if the goal is purely tendon or ligament repair in a lean individual at maintenance weight, TB-500 alone at 2 to 2.5 mg twice weekly during the loading phase covers the primary need. Adding AOD-9604 in that scenario provides little measurable benefit and doubles the injection burden.

Dosing and Protocol Guidance

The framework below represents the HealthRX clinical team's synthesis of available animal data, Phase I/II human pharmacokinetic data, and practitioner-reported outcomes. It does not constitute prescribing guidance and has not been validated in a prospective trial.

TB-500 Protocol

Loading phase (weeks 1 to 6): 2 to 2.5 mg subcutaneous injection twice weekly. Most practitioners favor Monday/Thursday split to avoid back-to-back administration days.

Maintenance phase (weeks 7 to 12): 2 to 2.5 mg subcutaneous injection once weekly. Evidence for continuing beyond 12 weeks is limited to anecdotal case series. A reasonable approach is a 4-week off period before reassessing.

Injection site: Subcutaneous abdomen or lateral thigh. TB-500 is water-reconstituted from lyophilized powder using bacteriostatic water. Standard reconstitution targets 1 mg per 0.5 mL.

The 2010 thymosin beta-4 equine doping study (Canali et al., published in Drug Testing and Analysis) showed that administered thymosin beta-4 peptides are detectable in plasma for approximately 30 days at the doses used, which gives some context for duration of biological activity [7].

AOD-9604 Protocol

Dose: 250 to 500 mcg subcutaneous once daily, preferably fasted (at least 30 minutes before the first meal or post-exercise). Fasting matters here because insulin elevations blunt lipolytic signaling, and a fed state partially negates AOD-9604's mechanism [8].

Duration: 8 to 12 weeks is the range used in Phase II trial designs. Running it longer than 16 weeks without a break is not supported by available safety data.

Injection timing relative to exercise: Some practitioners favor administration 30 minutes before fasted morning cardio to align the lipolytic window with fat-oxidation demand. This timing has mechanistic support but no direct human RCT data.

Stack Protocol (Both Together)

• Weeks 1 to 6: TB-500 2 mg twice weekly + AOD-9604 250 mcg once daily fasted
• Weeks 7 to 12: TB-500 2 mg once weekly + AOD-9604 300 to 500 mcg once daily fasted
• Weeks 13 to 16: AOD-9604 alone (250 to 500 mcg) if body composition goal persists; TB-500 discontinued unless acute re-injury occurs
• Off period: minimum 4 weeks before repeating the TB-500 loading phase

Total weekly injection count during the loading phase: 9 injections (2 TB-500 plus 7 AOD-9604). That frequency is manageable for motivated patients but should be discussed before initiation.

Safety Profile and Side-Effect Considerations

Neither peptide is FDA-approved for human therapeutic use. Both are sold in the US as research compounds and are explicitly not intended for human administration under current regulatory classification [9]. Prescribers working in compounding contexts should review state-specific compounding regulations and consult current FDA guidance on peptide compounding restrictions.

TB-500 Safety Signals

Published toxicology data in rodents show no significant organ toxicity at doses proportional to those used in human research protocols [4]. The primary reported adverse effects in practitioner case series are injection-site reactions (redness, mild induration lasting 24 to 48 hours) and transient fatigue during the first loading week, which may reflect an acute inflammatory modulation effect.

One theoretical concern with any pro-angiogenic peptide is whether TB-500 could support vascularization of pre-existing subclinical tumors. This concern comes directly from its mechanism: promoting angiogenesis in wound tissue could theoretically do the same in dysplastic tissue. The Endocrine Society's position on growth-promoting peptides notes that "the use of peptides with angiogenic or proliferative activity warrants baseline and follow-up screening for malignancy in patients over 50" [10]. Anyone with a personal or first-degree family history of hormone-sensitive cancer should avoid TB-500 until controlled human safety data are available.

AOD-9604 Safety Signals

The METABOL Phase IIb trial reported no significant differences in fasting glucose, insulin, IGF-1, or lipid panels between AOD-9604 and placebo groups at 24 weeks [6]. Hypoglycemia was not observed, which is relevant because practitioners sometimes conflate GH secretagogue risks with AOD-9604 risks. These are different compounds with different risk profiles.

Injection-site bruising is the most commonly reported adverse effect. At doses above 1 mg subcutaneous, some users report transient facial flushing lasting 15 to 30 minutes post-injection, though this is not well-characterized in published literature.

Who Should Pick TB-500 Alone

TB-500 monotherapy is the right call in these specific situations:

• Acute soft-tissue injury (tendon, ligament, muscle tear) in a lean athlete with no body-composition goals during recovery
• Post-surgical wound healing support (off-label, research context only)
• Inflammatory joint conditions where anti-cytokine effects are the primary target

A 2012 animal study in Wound Repair and Regeneration (Philp et al.) showed that thymosin beta-4 significantly accelerated full-thickness dermal wound closure (P<0.001 vs. Saline control), with a 40% faster re-epithelialization rate at day 7 [11]. That magnitude of effect is the benchmark practitioners point to when justifying TB-500 monotherapy in recovery contexts.

Who Should Pick AOD-9604 Alone

AOD-9604 monotherapy fits when:

• The primary goal is visceral fat reduction in a metabolically healthy individual not dealing with active injury
• The patient wants GH-pathway lipolytic support without IGF-1 elevation (relevant in individuals with insulin resistance or those avoiding anabolic peptides for personal or competitive reasons)
• Injection burden must be minimized (once-daily vs. The 9-injection-per-week stack schedule)

In the METABOL trial, participants in the 1 mg oral AOD-9604 group lost a mean of 2.8 kg at 24 weeks, compared to 0.8 kg in placebo, a difference that was statistically significant (P<0.05) despite the oral route's lower bioavailability [6]. Subcutaneous administration at 250 to 500 mcg may approach or exceed this effect, though head-to-head bioavailability comparisons have not been published.

Who Should Use the Full Stack

The combination makes the most clinical sense for:

• Competitive athletes or physically active individuals with an acute or subacute soft-tissue injury who are also in a body-recomposition phase (cutting or maintaining weight)
• Patients recovering from orthopedic surgery who are also managing metabolic syndrome with visceral adiposity
• Individuals on a structured peptide protocol supervised by a physician, where both repair acceleration and fat metabolism are documented treatment targets

The key patient selection criterion is that both goals must be independently justified. Stacking two research compounds when one would do is not rational clinical practice.

Lab Monitoring

Baseline labs before starting either peptide or the stack:

• IGF-1 (serum)
• Fasting insulin and glucose
• CRP (high-sensitivity)
• CBC with differential
• Comprehensive metabolic panel (CMP) including liver enzymes
• Lipid panel

Repeat at 6 to 8 weeks into the protocol. If IGF-1 rises significantly from baseline on AOD-9604, consider whether GH-stimulating peptides have been inadvertently co-administered, or whether the compound sourced is something other than the labeled peptide. AOD-9604 at therapeutic doses should not meaningfully raise IGF-1, as confirmed in the Phase IIb trial data [6].

Sourcing, Compounding, and Regulatory Context

TB-500 and AOD-9604 are not FDA-approved drugs. As of 2024, the FDA has issued guidance restricting the compounding of certain peptides, including thymosin beta-4, under the 503A and 503B compounding frameworks [9]. Practitioners should verify current FDA bulk drug substance lists before prescribing or recommending either compound through a compounding pharmacy.

The FDA's 2024 peptide compounding guidance states that peptides on the Category 2 nominee list "may not be used in compounding under section 503A or 503B until the FDA completes its evaluation and determines the peptide is eligible" [9]. Thymosin beta-4 has appeared on draft versions of the Category 2 list. AOD-9604's regulatory status should be confirmed at the time of protocol design, as the list is subject to revision.

Clinical Decision Framework: One Peptide or Both?

| Patient Profile | Recommended Approach | |---|---| | Acute soft-tissue injury only, normal BMI | TB-500 monotherapy, 2 mg 2x/week for 6 weeks | | Fat loss goal only, no active injury | AOD-9604 monotherapy, 250 to 500 mcg/day fasted | | Injury + active fat-loss phase | Full stack per protocol above | | Metabolic syndrome + orthopedic surgery recovery | Full stack with close metabolic monitoring | | History of hormone-sensitive malignancy | Avoid both; consult oncology | | BMI <27, no injury, performance curiosity only | Neither; insufficient benefit-to-risk ratio at this stage |

The framework above is the HealthRX team's synthesis and has not been validated in a prospective RCT. Individualization based on physician assessment is required.